AstraZeneca’s shareholders oppose bonus to Pascal Soriot (GBP9.4m) and his team

AstraZeneca’s shareholders today have expressed their opposition to the proposed bonus package to CEO Pascal Soriot and his team. Soriot in 2017 received GBP9.4m, which is considerably below his 2016 salary–as much as GBP14.3m. Despite this, shareholders object that EPS–what really makes a difference for a shareholder–in 2017 dropped by 14% and EBITDA dropped by 25%. Importantly, only 60% of shareholders last year approved the bonus to Pascal Soriot, who has received, on average, 87% of the maximum bonus allowed since he became CEO.

(Source: FT)